Non-Hodgkin Lymphoma Outcomes at KFSYSCC

Between 2013-2017, the five-year survival rate for Non-Hodgkin Lymphoma at KFSYSCC was 73% vs 54% for other hospitals in Taiwan.

Basic Information and Distribution of 1,832 Non-Hodgkin Lymphoma Patients at KFSYSCC from 1990-2019

  
    


    
    
    




    
            
            Total
            1990-1994
            1995-1999
            2000-2004
            2005-2009
            2010-2014
            2015-2019
        

    
            n
            1,832
            40 (2%)
            143 (8%)
            401 (22%)
            422 (23%)
            437 (24%)
            389 (21%)
        

            Gender (%)
        

            Male
            964 (53%)
            20 (50%)
            74 (52%)
            214 (53%)
            215 (51%)
            237 (54%)
            204 (52%)
        

            Female
            868 (47%)
            20 (50%)
            69 (48%)
            187 (47%)
            207 (49%)
            200 (46%)
            185 (48%)
        

            Age
        

            Mean/Median
            55/56
            49/52
            52/57
            52/53
            55/56
            56/57
            57/59
        

            Range
            2-100
            13-73
            2-87
            4-93
            12-100
            10-90
            8-90
        

            Q1-Q3
            44-66
            35-65
            39-67
            41-65
            45-66
            46-66
            46-67
        

            Stage (%)
        

            I
            310 (17%)
            5 (13%)
            8 (6%)
            51 (13%)
            84 (20%)
            88 (20%)
            74 (19%)
        

            II
            313 (17%)
            5 (13%)
            16 (11%)
            50 (12%)
            65 (15%)
            83 (19%)
            94 (24%)
        

            III
            349 (19%)
            7 (18%)
            13 (9%)
            47 (12%)
            57 (14%)
            111 (25%)
            114 (29%)
        

            IV
            374 (20%)
            4 (10%)
            10 (7%)
            48 (12%)
            103 (24%)
            120 (27%)
            89 (23%)
        

            Unknown
            486 (27%)
            19 (48%)
            96 (67%)
            205 (51%)
            113 (27%)
            35 (8%)
            18 (5%)
        






  

	Total	1990-1994	1995-1999	2000-2004	2005-2009	2010-2014	2015-2019
n	1,832	40 (2%)	143 (8%)	401 (22%)	422 (23%)	437 (24%)	389 (21%)
Gender (%)
Male	964 (53%)	20 (50%)	74 (52%)	214 (53%)	215 (51%)	237 (54%)	204 (52%)
Female	868 (47%)	20 (50%)	69 (48%)	187 (47%)	207 (49%)	200 (46%)	185 (48%)
Age
Mean/Median	55/56	49/52	52/57	52/53	55/56	56/57	57/59
Range	2-100	13-73	2-87	4-93	12-100	10-90	8-90
Q1-Q3	44-66	35-65	39-67	41-65	45-66	46-66	46-67
Stage (%)
I	310 (17%)	5 (13%)	8 (6%)	51 (13%)	84 (20%)	88 (20%)	74 (19%)
II	313 (17%)	5 (13%)	16 (11%)	50 (12%)	65 (15%)	83 (19%)	94 (24%)
III	349 (19%)	7 (18%)	13 (9%)	47 (12%)	57 (14%)	111 (25%)	114 (29%)
IV	374 (20%)	4 (10%)	10 (7%)	48 (12%)	103 (24%)	120 (27%)	89 (23%)
Unknown	486 (27%)	19 (48%)	96 (67%)	205 (51%)	113 (27%)	35 (8%)	18 (5%)

Based on KFSYSCC's cancer registry from 1990 to 2019, there were 1,832 analytic non-Hodgkin lymphoma cases, with 964 males (53%) and 868 females (47%). The average and median ages were 55 and 56 years old, respectively; the youngest patient was 2 years old, and the oldest was 100 years old; the interquartile range (Q1-Q3) was 44-66. By stage, there were 310 stage 1 patients (17%), 313 stage II patients (17%), 349 stage III patients (19%), and 374 stage IV patients (20%) The basic information and stage distribution of all non-Hodgkin Lymphoma patients, sorted by the year of diagnosis, are presented in the table below.

Survival curves for non-Hodgkin lymphoma patients stratified by year of diagnosis from 1990 to 2019, showing decreasing probability of overall survival over years after diagnosis.

Survival Curves for 1,832 Non-Hodgkin Lymphoma Patients (1990-2019), Stratified by Year of Diagnosis

From 1990 to 2019, the chart illustrates the five-year observed survival rates for 1,832 non-Hodgkin lymphoma patients at KFSYSCC, stratified by the year of diagnosis. The graph shows the five-year survival rate for non-Hodgkin lymphoma increased from 55% in 1990-1994 to 77% in 2015-2019, while the ten-year survival rate rose from 46% in 1990-1994 to 61% in 2010-2014.

Treatment Methods and Stages for 389 Non-Hodgkin Lymphoma Patients at KFSYSCC (2015-2019)

  
    


    
    
    


    
    
        
            Treatment Type
            Total
            Stage I
            Stage II
            Stage III
            Stage IV
            Unknown
        

            Total
            389
            74
            94
            114
            89
            18
        

            Surgical Treatment
            15 (4%)
            5 (7%)
            2 (2%)
            2 (2%)
            2 (2%)
            4 (22%)
        

            Radiation Therapy
            127 (33%)
            33 (45%)
            56 (60%)
            19 (17%)
            13 (15%)
            6 (33%)
        

            Chemotherapy
            317 (81%)
            48 (65%)
            84 (89%)
            92 (81%)
            82 (92%)
            11 (61%)
        

            Targeted Therapy
            262 (67%)
            40 (54%)
            68 (72%)
            82 (72%)
            66 (74%)
            6 (33%)
        

            Hormone Therapy
            217 (56%)
            29 (39%)
            64 (68%)
            66 (58%)
            53 (60%)
            5 (28%)
        

            Immunotherapy
            21 (5%)
            6 (8%)
            5 (5%)
            10 (9%)
            0 (0%)
            0 (0%)
        

            Palliative Care
            6 (2%)
            2 (3%)
            0 (0%)
            2 (2%)
            1 (1%)
            1 (6%)
        

            Bone Marrow/Stem Cell Transplant
            18 (5%)
            2 (3%)
            2 (2%)
            9 (8%)
            3 (3%)
            2 (11%)
        

            No Record of Initial Treatment Reported
            27 (7%)
            10 (14%)
            5 (5%)
            7 (6%)
            4 (4%)
            1 (6%)
        





  

Treatment Type	Total	Stage I	Stage II	Stage III	Stage IV	Unknown
Total	389	74	94	114	89	18
Surgical Treatment	15 (4%)	5 (7%)	2 (2%)	2 (2%)	2 (2%)	4 (22%)
Radiation Therapy	127 (33%)	33 (45%)	56 (60%)	19 (17%)	13 (15%)	6 (33%)
Chemotherapy	317 (81%)	48 (65%)	84 (89%)	92 (81%)	82 (92%)	11 (61%)
Targeted Therapy	262 (67%)	40 (54%)	68 (72%)	82 (72%)	66 (74%)	6 (33%)
Hormone Therapy	217 (56%)	29 (39%)	64 (68%)	66 (58%)	53 (60%)	5 (28%)
Immunotherapy	21 (5%)	6 (8%)	5 (5%)	10 (9%)	0 (0%)	0 (0%)
Palliative Care	6 (2%)	2 (3%)	0 (0%)	2 (2%)	1 (1%)	1 (6%)
Bone Marrow/Stem Cell Transplant	18 (5%)	2 (3%)	2 (2%)	9 (8%)	3 (3%)	2 (11%)
No Record of Initial Treatment Reported	27 (7%)	10 (14%)	5 (5%)	7 (6%)	4 (4%)	1 (6%)

Between 2015 and 2019, there were a total of 389 analytic non-Hodgkin lymphoma cases, including 74 patients in stage I, 94 in stage II, 114 in stage III, and 89 in stage IV. In terms of treatment methods, 15 patients (4%) underwent surgical treatment, 127 (33%) received radiation therapy, 317 (81%) underwent chemotherapy, 262 (67%) received targeted therapy, 217 (56%) received hormone therapy, 21 (5%) received immunotherapy, 6 (2%) underwent palliative care, 18 (5%) received bone marrow or stem cell transplantation, and 27 (7%) had no record of initial treatment reported.

A line graph displaying five-year survival rates of 389 Non-Hodgkin Lymphoma patients categorized by stage from 2015 to 2019. The graph shows overall survival probability over time, with different lines representing stages I through IV and unknown stage. Survival decreases over time, with stage-specific rates at five years being 85% for stage I, 89% for stage II, 69% for stage III and IV, and unspecified for unknown stage.

Five-Year Survival Rates of 389 Non-Hodgkin Lymphoma Patients by Stage (2015-2019)

KFSYSCC’s 2015-2019 five-year observed survival rates for 389 non-Hodgkin lymphoma patients, stratified by stage, are presented in the following chart. As shown in the graph, the five-year survival rate is 85% for stage 1, 89% for stage 2, 69% for stage 3, and 69% for stage 4.